INNOVATION THAT MATTERS

Solid as a Rock: Creating a Strong Foundation for Developing First-in-Class Treatments to Fight...

By Rich Soll, Senior Vice President, Research Service Division, WuXi AppTec (@richsollwx) In the life sciences, disruptive innovation is no longer the exception; it’s the rule. One global R&D executive known for...

Brave Science: Putting the ‘Hutzpah’ in Early-Stage Drug Discovery

By Rich Soll, SVP of Research Service Division at WuXi AppTec (@richsollwx) From developing new paradigms for early-stage drug discovery for rare and common diseases to fostering the convergence of peptide nanotechnology, and launching...

INDUSTRY BEATS

WUXI NEWS

WuXi AppTec Acquires Biology Focused R&D Service Leader HD Biosciences

We are excited to announce that WuXi has acquired HD Biosciences (HDB), a leading biology focused preclinical drug discovery contract research organization (CRO). After completion of acquisition, HD Biosciences will become...

FDA DRUG APPOVALS / DESIGNATIONS

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS

Rejuvenation: The Role of Plasma Proteins in Counterbalancing Aging

The explosion of new biotechnologies and access and understanding of newly mined genomic information has spurred biotech companies and researchers into developing new therapies...